Skip to main content

Branded

  • Senate committee reports pharmaceutical gray market fueled by unscrupulous pharmacies

    WASHINGTON — The Senate Committee on Commerce, Science and Transportation on Wednesday released a staff report on the investigation into the gray market for pharmaceuticals — what the committee defined as "shady operators who make enormous profits by buying hard-to-find drugs and reselling them at huge markups" — specifically naming pharmacies as a primary culprit.

  • Pfizer, J&J drug appears ineffective in some Alzheimer's patients

    NEW YORK — An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.

  • Court rules in favor of Pfizer, Northwestern University in Lyrica patent case

    NEW YORK — A district court ruled in favor of Pfizer and Northwestern University in a patent infringement case relating to Lyrica (pregabalin).

  • FDA approves new COPD drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

    The FDA announced the approval of Tudorza Pressair (aclidinium bromide) for the long-term maintenance of COPD-related narrowing of the airways in the lung, also known as bronchospasm. The drug is an inhaled dry powder used twice per day.

  • Pfizer pain drug doesn't affect sperm production, study finds

    NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

    The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

  • FDA approves Afinitor for advanced breast cancer

    EAST HANOVER, N.J. — The Food and Drug Administration has approved a new use for a Novartis cancer drug.

    The drug maker said Friday that the FDA had approved Afinitor (everolimus) combined with exemestane for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer who have failed treatment with letrozole or anastrozole.

  • Bausch + Lomb survey reveals need for eye health education

    ROCHESTER, N.Y. — Less than one-third of people take the basic steps necessary to preserve eye sight, according to a Bausch + Lomb global survey released last week. Though if forced to choose, people would rather lose their sense of taste (79%), hearing (78%), one of their limbs (68%) or 10 years off their life (67%) instead of their eyesight.

  • FDA approves blood cancer drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating multiple myeloma, the agency said Friday.

X
This ad will auto-close in 10 seconds